- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05459688
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
An Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124 to Evaluate the Long-Term Safety and Effectiveness of CIN-107
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Saraland, Alabama, United States, 36571
- Research Site
-
-
California
-
Huntington Park, California, United States, 90255
- Research Site
-
Lincoln, California, United States, 95648
- Research Site
-
Los Angeles, California, United States, 90057
- Research Site
-
Northridge, California, United States, 91324
- Research Site
-
Oceanside, California, United States, 92056
- Research Site
-
Panorama City, California, United States, 91402
- Research Site
-
Van Nuys, California, United States, 91405
- Research Site
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Research Site
-
Doral, Florida, United States, 33166
- Research Site
-
Hialeah, Florida, United States, 33012
- Research Site
-
Hollywood, Florida, United States, 33024
- Research Site
-
Lake Worth, Florida, United States, 33467
- Research Site
-
Miami, Florida, United States, 33173
- Research Site
-
Miami, Florida, United States, 33165
- Research Site
-
Pembroke Pines, Florida, United States, 33027
- Research Site
-
Winter Haven, Florida, United States, 33880
- Research Site
-
-
Illinois
-
Addison, Illinois, United States, 60101
- Research Site
-
Chicago, Illinois, United States, 60607
- Research Site
-
Morton, Illinois, United States, 61550
- Research Site
-
-
Indiana
-
Brownsburg, Indiana, United States, 46112
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70124
- Research Site
-
-
Michigan
-
Troy, Michigan, United States, 48085
- Research Site
-
-
Mississippi
-
Olive Branch, Mississippi, United States, 38654
- Research Site
-
-
New York
-
Brooklyn, New York, United States, 11235
- Research Site
-
-
Ohio
-
Columbus, Ohio, United States, 43213
- Research Site
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- Research Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Research Site
-
Carrollton, Texas, United States, 75006
- Research Site
-
Dallas, Texas, United States, 75234
- Research Site
-
Georgetown, Texas, United States, 78628
- Research Site
-
Houston, Texas, United States, 77040
- Research Site
-
Lampasas, Texas, United States, 76550
- Research Site
-
San Antonio, Texas, United States, 78209
- Research Site
-
-
Utah
-
West Valley City, Utah, United States, 84120
- Research Site
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Have completed Part 1 or Part 2 of Study CIN-107-124;
- Have had acceptable safety and tolerability during Study CIN-107-124 as determined by the Investigator or Medical Monitor;
- Have demonstrated ≥70% and ≤120% adherence to their single background antihypertensive agent and the CIN-107 placebo during Study CIN-107-124;
Agree to comply with the contraception and reproduction restrictions of the study as follows:
- Male patients must agree to abstain from sperm donation from Day 1 through 90 days after the final dose of study drug;
- Female patients of childbearing potential (ie, ovulating, pre-menopausal, and not surgically sterile) must have a documented negative serum pregnancy test at enrollment (Visit 1); and
- Female patients of childbearing potential must use a highly effective method of contraception (ie, <1% failure rate) from Day 1 through 30 days after the last administration of study drug.
- Are able and willing to give informed consent for participation in the clinical study.
Exclusion Criteria:
- Have met Protocol-defined stopping criteria, were withdrawn from the study, discontinued CIN-107 at the time of Visits 6 or 9, or were not compliant with the Protocol during Study CIN-107-124;
- Have received treatment with any investigational agent for disease intervention (ie, other than study drug) during Study CIN-107-124, or since the last administration of study drug in Study CIN-107-124, or plans to participate in another clinical study within 30 days of discontinuation of study drug;
- Have had any new, significant, or uncontrolled comorbidity since initially enrolling in Study CIN-107-124 that would increase the risk of the patient in Study CIN-107-130, as determined by the Investigator;
- Have had a mean seated SBP ≥170 mmHg or DBP ≥105 mmHg at the end of Part 1 or Part 2 of Study CIN-107-124;
- Have an upper arm circumference that does not meet the cuff measurement criteria for the selected BP machine at Visit 1 of Study CIN-107-130;
- Have any uncontrolled or clinically significant laboratory abnormality that would affect safety, interpretation of study data, or the patient's participation in the study, as determined by the Investigator;
- Have experienced a de novo or reactivated serious viral infection such as hepatitis B, hepatitis C, or HIV during Study CIN-107-124;
- Have had any major episode of infection requiring hospitalization or treatment with intravenous antibiotics during Study CIN-107-124;
- Have developed a malignancy (with the exception of non-serious local and resectable basal or squamous cell carcinoma of the skin) during Study CIN-107-124;
- Have anticipated initiation of erythropoietin-stimulating agents and/or planned transfusion within 2 months after enrollment (Visit 1);
- Are expected to receive or are receiving any of the exclusionary drugs (strong cytochrome P450 3A inducers);
- Have known secondary causes of HTN (eg, renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome, or aortic coarctation) except obstructive sleep apnea;
- Have been diagnosed with New York Heart Association stage III or IV chronic heart failure during Study CIN-107-124;
- Have had a stroke, transient ischemic attack, hypertensive encephalopathy, acute coronary syndrome, or hospitalization for heart failure during Study CIN-107-124;
- Have a known current severe left ventricular outflow obstruction, such as obstructive hypertrophic cardiomyopathy and/or severe aortic valvular disease diagnosed from a prior echocardiogram;
- Have a planned coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]) or any major surgical procedure;
- Have had a CABG or other major cardiac surgery (eg, valve replacement), peripheral arterial bypass surgery, or PCI during Study CIN-107-124;
- Have a planned dialysis or kidney transplant during the course of this study;
- Have a known hypersensitivity to CIN-107 or drugs of the same class, or any of its excipients;
- Have any clinically relevant medical or surgical conditions (including unstable conditions and/or treatment with systemic immunosuppressants including corticosteroids) that, in the opinion of the Investigator, would put the patient at risk by participating in the study;
- Are pregnant, breastfeeding, or planning to become pregnant during the study; or
- Are considered to be unsuitable for any other reason that may either place the patient at increased risk during participation or interfere with the interpretation of the study outcomes by the Investigator, after reviewing medical and psychiatric history, physical examination, and laboratory evaluation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental 2 mg CIN-107 tablets QD
Treatment with 2 mg CIN-107 tablets, by mouth, once per day.
Starting at Visit 1 and concluding at EOT (Visit 7).
|
2 mg of CIN-107, once a day for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate the long-term safety and tolerability of CIN-107
Time Frame: up to 52 weeks
|
Evaluate TEAEs Evaluate treatment-emergent SAEs Evaluate TEAEs of special interest Evaluate TEAEs leading to treatment premature discontinuation Evaluate treatment-emergent marked laboratory abnormalities Evaluate the change on standing SBP and diastolic BP, measured pre-dose at the clinical site, from baseline (V1) to (EOT) Evaluate vital signs, standing BP and heart rate, physical examinations, ECGs, weight, clinical lab evaluations, including standard chemistry panel, hematology, coagulation and urinalysis
|
up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean systolic blood pressure (SBP) change
Time Frame: over 52 weeks
|
over 52 weeks
|
|
Mean diastolic blood pressure (DBP) change
Time Frame: over 52 weeks
|
over 52 weeks
|
|
Percentage of patients achieving a seated SBP <130 mmHg
Time Frame: over 52 weeks
|
over 52 weeks
|
|
Percentage of non-responders in Study CIN-107-124 achieving a seated SBP response <130 mmHg with CIN-107
Time Frame: over 52 weeks
|
With/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength
|
over 52 weeks
|
Percentage of responders in Study CIN-107-124 maintaining a seated SBP response <130 mmHg with CIN-107
Time Frame: over 52 weeks
|
With/without a single background antihypertensive agent and/or rescue medication and irrespective of Study CIN-107-124 dose strength
|
over 52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIN-107-130
- D6971C00001 (Other Identifier: AstraZeneca)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on CIN-107
-
AstraZenecaActive, not recruitingPrimary Aldosteronism | HyperaldosteronismUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedStudy to Evaluate the Pharmacokinetics of CIN-107 in Subjects With Varying Degrees of Renal FunctionHypertensionUnited States
-
AstraZenecaParexelActive, not recruitingChronic Kidney Diseases | Uncontrolled HypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompletedHypertensionUnited States
-
AstraZenecaCompleted
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionArgentina, China, Korea, Republic of, Vietnam, Japan, Philippines, Hong Kong, Turkey, India, Australia, Russian Federation
-
AstraZenecaRecruitingResistant HypertensionSpain, Argentina, United States, Belgium, Czechia, Vietnam, Thailand, Australia, Turkey, Philippines, Greece, Taiwan, United Kingdom, Poland, South Africa, Canada, Germany, Hungary, Malaysia, Bulgaria, Saudi Arabia, Slovakia
-
AstraZenecaRecruitingResistant Hypertension | Uncontrolled HypertensionUnited States, Canada, Italy, South Africa, Korea, Republic of, Australia, Belgium, France, Germany, Poland, Japan, Spain, Vietnam, Argentina, Bulgaria, Turkey, India, Malaysia, Taiwan, Thailand, Austria, Israel, Netherlands, Sweden, United... and more